Also trades as: 0IV3.L (LSE) · $vol 0M
GERN NASDAQ
Geron Corporation
1W: -7.3%
1M: -8.0%
3M: -17.9%
YTD: -12.9%
1Y: -7.3%
3Y: -35.0%
5Y: -19.0%
$1.15
+0.00 (+0.00%)
Weekly Expected Move ±5.4%
$1
$1
$1
$1
$1
Credit Risk of going bust: higher than 60% of companies Debt: 14.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 98%), Geron Corporation would be worth roughly what it owes.
Total debt $122.1M against a stock market value of $738.8M.
Distance to default 4.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $60.1M (short-term plus half of long-term), stock volatility 62.8%; Altman Z'' -6.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 98%), Geron Corporation would be worth roughly what it owes.
Total debt $122.1M against a stock market value of $738.8M.
Distance to default 4.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $60.1M (short-term plus half of long-term), stock volatility 62.8%; Altman Z'' -6.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$738.8M
52W Range1.04-2.01
Volume6,666,693
Avg Volume10,438,045
Beta0.61
Dividend—
Analyst Ratings
Company Info
CEOHarout Semerjian
Employees258
SectorHealthcare
IndustryBiotechnology
IPO Date1996-07-31
Websitegeron.com
919 East Hillsdale Boulevard
Foster City, CA 94404
US
Foster City, CA 94404
US
650 473 7700
About Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Latest News
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
ADAR1 Capital Management LLC Invests $647,000 in Geron Corporation $GERN
Geron (NASDAQ:GERN) Shares Up 6.4% - Here's What Happened - MarketBeat
Geron (GERN) Is Up 15.6% After Raising 2026 RYTELO Revenue Guidance And Filing New ESOP Shares - simplywall.st
Geron Corporation $GERN Stake Raised by Renaissance Technologies LLC - MarketBeat
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Spiegel Robert J. | A-Award | 6,351 | $1.23 | 2026-09-30 |
| Spiegel Robert J. | A-Award | 6,103 | $1.28 | 2026-06-30 |
| Spiegel Robert J. | A-Award | 220,000 | $1.26 | 2026-05-20 |
| O'Farrell Elizabeth | A-Award | 220,000 | $1.26 | 2026-05-20 |
| Molineaux Susan | A-Award | 220,000 | $1.26 | 2026-05-20 |